Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for...
Maier et al., Mol Ther. 2013 Jun25 (Epub doi: 10.1038/mt.2013.124) Abstract In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have...
View ArticlePositive Phase II Clinical Data with ALN-TTR02
We presented positive data from our Phase II clinical trial of ALN-TTR02 for the treatment of transthyretin-mediated amyloidosis (ATTR) at the Biennial Meeting of the Peripheral Nerve Society being...
View ArticleR&D Day 2013 Podcast and Presentations
On July 11, we hosted an R&D Day in New York City. Alnylam scientists and management reviewed progress with our Alnylam 5×15 pipeline for the development and commercialization of RNAi therapeutics....
View ArticlePositive Clinical Trial Results with ALN-TTR01 and ALN-TTR02 Published in the...
We have published complete study results from Phase I trials with ALN-TTR01 and ALN-TTR02 in the New England Journal of Medicine. RNAi therapeutics targeting transthyretin (TTR) achieved rapid,...
View ArticlePositive Clinical Results from Phase I Trial of ALN-TTRsc
We have reported positive clinical results from our Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated...
View ArticlePositive Phase I Clinical Trial Results with ALN-PCS Published in “The Lancet”
We have published complete study results from our Phase I trial with ALN-PCS in The Lancet. As reported in the paper, ALN-PCS administration resulted in a rapid, dose-dependent reduction in plasma...
View ArticleNew Pre-Clinical Data on ALN-AS1 for the Treatment of Porphyria and PK/PD...
We presented new pre-clinical data supporting the selection of the ALN-AS1 Development Candidate for the treatment of hepatic porphyrias, including acute intermittent porphyria (AIP). The new research,...
View ArticleNew Pre-Clinical Data on ALN-AAT for the Treatment of Alpha-1-Antitrypsin...
We presented new pre-clinical data on ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of liver disease associated with AAT deficiency. These data were...
View ArticlePositive Phase II Data with Patisiran (ALN-TTR02)
We presented positive data from our Phase II clinical trial of patisiran (ALN-TTR02) for the treatment of transthyretin-mediated amyloidosis (ATTR) at the International Symposium on Familial...
View ArticleNew Pre-Clinical Data on ALN-PCSsc and ALN-ANG Presented at AHA
We presented new pre-clinical data with RNAi therapeutic programs for cardiovascular disease: ALN-PCSsc, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; and ALN-ANG, an...
View ArticlePre-Clinical Data from “Alnylam 5×15” Programs Presented at ASH 2013
We presented pre-clinical data from three programs within our “Alnylam 5×15” RNAi therapeutic pipeline: ALN-AT3 for the treatment of hemophilia and rare bleeding disorders (RBD), ALN-CC5 for the...
View ArticlePre-Clinical Data on Pharmacology of GalNAc-siRNA Conjugates
We presented new pre-clinical data on the pharmacology of GalNAc-siRNA conjugates at the 12th US-Japan Symposium on Drug Delivery Systems held December 16 – 20, 2013 in Lahaina, Maui, Hawaii. These new...
View Article